CardioSignal, a tech-enabled heart disease detection company, has secured $10 million in Series A funding, bringing its total raise to $23 million. DigiTx Partners led the round with participation from Sandwater and existing investor Maki.vc. The company uses gyroscope and accelerometer motion data from smartphone sensors to analyze cardiac motion and detect heart diseases. The funds will be used to conduct clinical studies and expand commercial efforts. CardioSignal plans to launch new capabilities for detecting heart failure and aortic stenosis in European markets followed by the United States. The company has formed partnerships with pharmaceutical companies and has been part of numerous research studies.
Source link
CardioSignal scores $10M for heart disease detection technology
